On the stock market since 2010, it operates in the world of health and science. It has 146 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $70.4M a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $5.00 — 106% above today’s price.
A loss of $44.0M against $70.4M in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, CDXS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CDXS is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (47/100) says the stock isn’t cheap.